20/20 Biolabs director converts preferred to common

Q: How many preferred shares did John Woodson Rollins convert in the 20/20 Biolabs (AIDX) Form 4?

He converted 13,029 shares of Series A preferred stock and 6,135 shares of Series A-2 preferred stock. Each preferred share automatically became one common share upon the Nasdaq Capital Market listing of 20/20 Biolabs’ common stock on February 19, 2026.

Q: Were the 20/20 Biolabs (AIDX) insider transactions open-market buys or sells?

The transactions were derivative conversions, not open-market buys or sells. Series A and Series A-2 preferred shares automatically converted into common stock at a stated price per share of $0.0000 when 20/20 Biolabs’ common stock listed on the Nasdaq Capital Market.

Q: What triggered the preferred-to-common conversion for 20/20 Biolabs (AIDX) insider shares?

The conversion was automatically triggered by the listing of 20/20 Biolabs’ common stock on the Nasdaq Capital Market. On February 19, 2026, all Series A and Series A-2 preferred shares held by the reporting person converted into an equivalent number of common shares.

20/20 Biolabs, Inc. director John Woodson Rollins reported automatic conversions of preferred stock into common shares.

Accepted by SEC EDGAR 02/23/2026 - 07:09 PM EST

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

20/20 Biolabs, Inc. director John Woodson Rollins reported automatic conversions of preferred stock into common shares. On February 19, 2026, 13,029 shares of Series A preferred and 6,135 shares of Series A-2 preferred were converted into an equivalent number of common shares upon the listing of the company’s common stock on the Nasdaq Capital Market. After these derivative conversions, he held 30,275 shares of common stock directly.

Insider Trade Summary

19,164 shares exercised/converted

Exercise 4 txns

Insider Rollins John Woodson

Role Director

Type	Security	Shares	Price	Value
Conversion	Series A Preferred Stock	13,029	$0.00	$0.00
Conversion	Series A-2 Preferred Stock	6,135	$0.00	$0.00
Conversion	Common Stock	13,029	$0.00	$0.00
Conversion	Common Stock	6,135	$0.00	$0.00

Holdings After Transaction: Series A Preferred Stock — 0 contracts (Direct); Series A-2 Preferred Stock — 0 contracts (Direct); Common Stock — 30,275 shares (Direct)

Footnotes (2)

F1. On February 19, 2026, all shares of series A preferred stock held by the Reporting Person were automatically converted into an equivalent number of shares of common stock upon the listing of the Issuer's common stock on the Nasdaq Capital Market. The series A preferred stock had no expiration date.
F2. On February 19, 2026, all shares of series A-2 preferred stock held by the Reporting Person were automatically converted into an equivalent number of shares of common stock upon the listing of the Issuer's common stock on the Nasdaq Capital Market. The series A-2 preferred stock had no expiration date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did 20/20 Biolabs (AIDX) report for John Woodson Rollins?

John Woodson Rollins reported automatic conversions of preferred stock into common stock. On February 19, 2026, his Series A and Series A-2 preferred shares converted into an equivalent number of common shares following the Nasdaq Capital Market listing of 20/20 Biolabs’ common stock.

How many preferred shares did John Woodson Rollins convert in the 20/20 Biolabs (AIDX) Form 4?

He converted 13,029 shares of Series A preferred stock and 6,135 shares of Series A-2 preferred stock. Each preferred share automatically became one common share upon the Nasdaq Capital Market listing of 20/20 Biolabs’ common stock on February 19, 2026.

How many 20/20 Biolabs (AIDX) common shares does John Woodson Rollins own after these conversions?

Following the reported derivative conversions, John Woodson Rollins directly owns 30,275 shares of common stock of 20/20 Biolabs. This total reflects the addition of common shares received from the automatic conversion of his Series A and Series A-2 preferred stock on February 19, 2026.

Were the 20/20 Biolabs (AIDX) insider transactions open-market buys or sells?

The transactions were derivative conversions, not open-market buys or sells. Series A and Series A-2 preferred shares automatically converted into common stock at a stated price per share of $0.0000 when 20/20 Biolabs’ common stock listed on the Nasdaq Capital Market.

What triggered the preferred-to-common conversion for 20/20 Biolabs (AIDX) insider shares?

The conversion was automatically triggered by the listing of 20/20 Biolabs’ common stock on the Nasdaq Capital Market. On February 19, 2026, all Series A and Series A-2 preferred shares held by the reporting person converted into an equivalent number of common shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Rollins John Woodson

(Last)

(First)

(Middle)

C/O 20/20 BIOLABS, INC.

15810 GAITHER ROAD, SUITE 235

(Street)

GAITHERSBURG

20877

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
20/20 Biolabs, Inc. [ AIDX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/19/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	02/19/2026		C⁽¹⁾		13,029	A	$0	24,140	D
Common Stock	02/19/2026		C⁽²⁾		6,135	A	$0	30,275	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Series A Preferred Stock⁽¹⁾	⁽¹⁾	02/19/2026		C⁽¹⁾			13,029	⁽¹⁾	⁽¹⁾	Common Stock	13,029	⁽¹⁾	0	D
Series A-2 Preferred Stock⁽²⁾	⁽²⁾	02/19/2026		C⁽²⁾			6,135	⁽²⁾	⁽²⁾	Common Stock	6,135	⁽²⁾	0	D

Explanation of Responses:

1. On February 19, 2026, all shares of series A preferred stock held by the Reporting Person were automatically converted into an equivalent number of shares of common stock upon the listing of the Issuer's common stock on the Nasdaq Capital Market. The series A preferred stock had no expiration date.

2. On February 19, 2026, all shares of series A-2 preferred stock held by the Reporting Person were automatically converted into an equivalent number of shares of common stock upon the listing of the Issuer's common stock on the Nasdaq Capital Market. The series A-2 preferred stock had no expiration date.

	/s/ John W. Rollins	02/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR